KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Payables (2016 - 2025)

Historic Payables for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Q3 2025 value amounting to $3.8 million.

  • Rigel Pharmaceuticals' Payables rose 81.26% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year increase of 81.26%. This contributed to the annual value of $3.3 million for FY2024, which is 5324.84% down from last year.
  • According to the latest figures from Q3 2025, Rigel Pharmaceuticals' Payables is $3.8 million, which was up 81.26% from $7.3 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' 5-year Payables high stood at $22.5 million for Q4 2022, and its period low was $1.7 million during Q2 2021.
  • Moreover, its 5-year median value for Payables was $4.6 million (2022), whereas its average is $5.8 million.
  • In the last 5 years, Rigel Pharmaceuticals' Payables skyrocketed by 49309.62% in 2022 and then tumbled by 6826.91% in 2023.
  • Quarter analysis of 5 years shows Rigel Pharmaceuticals' Payables stood at $3.8 million in 2021, then surged by 493.1% to $22.5 million in 2022, then plummeted by 68.27% to $7.1 million in 2023, then plummeted by 53.25% to $3.3 million in 2024, then increased by 15.18% to $3.8 million in 2025.
  • Its last three reported values are $3.8 million in Q3 2025, $7.3 million for Q2 2025, and $4.0 million during Q1 2025.